Burna AI is a clinical intelligence platform that uses AI to automate CTCAE adverse event grading and streamline oncology workflow by reading clinical notes, labs, and patient data to deliver accurate, evidence-cited adverse event assessments in seconds. Built for cancer care teams, clinical trials, and oncology practices, it improves consistency, saves time, and enhances documentation quality.
BTBC Oncologic
BTBC Oncologic, Inc. develops OncoSol Prime™, a governed AI host‑modulation system that builds a “medical digital clone” for each patient. By forecasting health risks and generating personalized protocols, it reduces toxicity and hospitalizations—saving payers money. Our validated platform also serves as a reimbursable clinical decision‑support tool and a clinical trial endpoint. We are ready for clinical deployment and strategic partnerships.
BioAro
BioAro Inc. is a leading biotechnology company specializing in whole genome sequencing and advanced genetic analysis. With a strong commitment to personalized medicine, BioAro leverages cutting-edge genomic technologies to provide individuals, healthcare professionals, and researchers with comprehensive insights into genetic health, disease predisposition, and personalized wellness strategies. At the core of BioAro’s services is its whole genome sequencing platform, which delivers high-precision genetic data that empowers users to make informed health decisions. The company’s offerings extend beyond raw data by providing advanced interpretation through proprietary bioinformatics pipelines and AI-driven analytics. By transforming complex genetic information into actionable insights, BioAro enables early disease detection, risk assessment, and tailored treatment recommendations. BioAro is dedicated to bridging the gap between genomic science and real-world application by making genetic testing accessible and understandable. Its services cater to a diverse clientele, including individuals interested in proactive health management, clinicians seeking precision medicine solutions, and researchers aiming to advance genetic discoveries. The company also collaborates with pharmaceutical and healthcare organizations to support drug development and personalized therapeutics. With a focus on innovation and data security, BioAro upholds the highest standards of accuracy and confidentiality. Its state-of-the-art sequencing facilities adhere to rigorous quality controls, ensuring reliable results that users can trust. As the demand for personalized medicine grows, BioAro continues to expand its capabilities, staying at the forefront of genomic advancements to improve health outcomes and revolutionize the future of healthcare. | BioAro Inc., established in 2021, is a Canadian biotechnology company headquartered in Calgary, Alberta. The company specializes in precision health, health span, and longevity, integrating genomics, artificial intelligence (AI), and blockchain technologies to deliver personalized healthcare solutions. BioAro’s mission is to revolutionize personalized healthcare through its cutting-edge technologies, including the BioPhenome Lab, BioHealth software solutions, Biospan clinics, and biotech devices. The company’s vision focuses on extending human healthspan by integrating innovative approaches for a healthier future. BioAro operates internationally, with Headoffice in Calgary, Canada; and offices in Dubai, United Arab Emirates; and Almelo, The Netherlands, and United Kingdom reflecting its commitment to making personalized medicine accessible worldwide. BioAro aims to transform healthcare from reactive disease management to proactive health optimization, empowering individuals to take control of their health and well-being. | BioAro Inc. is a Calgary-based precision health biotechnology company advancing real-time, AI-driven multi-omics solutions for personalized medicine. Its PanOmiQ™ platform integrates genomic, epigenomic, pharmacogenomic, microbiome, and clinical data to deliver rapid, scalable insights that support early disease detection, tailored treatment strategies, and predictive healthcare. BioAro’s ecosystem improves clinical decision-making and expands precision medicine markets.
10ZiG Technology
10ZiG delivers secure, standardized, and centrally managed endpoints for healthcare organizations. Our Imprivata Ready thin clients, zero clients, and PC repurposing software enable safe access to clinical systems across VDI, DaaS, and cloud environments by reducing PHI exposure and supporting HIPAA-aligned security. 10ZiG helps healthcare leaders improve clinician experience while lowering TCO, risk, and operational complexity.